Inmazeb and Ebanga improve survival from Zaire ebolavirus when started early, but neither is licensed for Bundibugyo. For BDBV, aggressive supportive care — IV fluids, electrolytes, treatment of co-infections — remains the backbone, with experimental antivirals deployed under research protocols.
The Briefing · Monoclonal antibodies and supportive care